A biotech startup that aims to revive a failed drug candidate with a precision approach to treating Alzheimer’s just brought a big name on board: Nobel laureate Dr. Stanley Prusiner, a pioneer in researching prion diseases.

Prusiner, a biologist based at the University of California, San Francisco, will join Alzheon, Inc. as chair of the scientific advisory board, said Alzheon founder and CEO Dr. Martin Tolar.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • My mother has Alzheimer disease, since 2008. She has 72 years old, she does not speak any more. We have visit all fisicians in México but they do not give su any hope. What can l do for my mother? What kind of study she can take?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy